Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Emedgene optimizes the workflows involved in tertiary analysis for rare disease genomics and various germline research endeavors. It is specifically built to enhance the speed and reliability of interpreting, prioritizing, curating, and generating research reports for user-defined variants. By incorporating explainable AI (XAI) and automation, Emedgene boosts efficiency across diverse analysis workflows, including genomes, exomes, virtual panels, and targeted panels. The platform facilitates the integration of laboratory processes and NGS instruments with IT systems, streamlining and securing the entire workflow. With continuous advancements in science, technology, and demand, Emedgene empowers users to stay current by offering cutting-edge knowledge graph features, curation tools, and expert support throughout their research journey. Furthermore, it allows laboratories to increase their throughput without the need for additional personnel, thanks to XAI and automated processes. Ultimately, Emedgene enables the deployment of high-throughput workflows for whole genome sequencing (WGS), whole exome sequencing (WES), virtual panels, or targeted panels that seamlessly fit into the digital framework of any lab. This comprehensive approach ensures that researchers can focus on their discoveries while relying on robust technological support.
Description
Recursion is a leading TechBio innovator using artificial intelligence to radically improve how new medicines are discovered and developed. The company was founded on the idea that images of cells could be used to train AI systems to understand disease biology at scale. By combining data, machine learning models, and powerful computing, Recursion works to overcome the inefficiencies of traditional drug discovery. Its Recursion OS platform connects massive proprietary biological datasets with automated experimentation and AI-driven insights. This approach has produced a growing pipeline of potential therapies for oncology and rare diseases with high unmet medical needs. Recursion has demonstrated significant gains in speed, efficiency, and cost reduction compared to conventional pharmaceutical methods. Strategic partnerships with pharmaceutical companies and technology leaders expand the reach of its platform. The company also collaborates with NVIDIA to power its discovery efforts using BioHive-2, one of the most advanced supercomputers in biopharma. Together, these capabilities position Recursion as a leader in AI-driven drug discovery. Its ultimate goal is to deliver better medicines to patients through precision design and data-driven science.
API Access
Has API
API Access
Has API
Integrations
Illumina DRAGEN Secondary Analysis
Pricing Details
No price information available.
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
Illumina
Country
United States
Website
www.illumina.com/products/by-type/informatics-products/emedgene.html
Vendor Details
Company Name
Recursion
Country
United States
Website
www.recursion.com